CRVS
Income statement / Annual
Last year (2025), Corvus Pharmaceuticals Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Corvus Pharmaceuticals Inc's net income was -$15.28 M.
See Corvus Pharmaceuticals Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$105.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$847.00 K
|
$842.00 K
|
$0.00
|
| Gross Profit |
-$105.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$847.00 K
|
-$842.00 K
|
-$594.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$33.72 M
|
$19.39 M
|
$16.53 M
|
$24.47 M
|
$29.12 M
|
$31.83 M
|
$37.98 M
|
$38.59 M
|
$46.31 M
|
$29.36 M
|
| General & Administrative Expenses |
$9.25 M
|
$8.16 M
|
$6.88 M
|
$8.10 M
|
$9.52 M
|
$11.93 M
|
$10.88 M
|
$10.64 M
|
$10.22 M
|
$7.62 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$9.25 M
|
$8.16 M
|
$6.88 M
|
$8.10 M
|
$9.52 M
|
$11.93 M
|
$10.88 M
|
$10.64 M
|
$10.22 M
|
$7.62 M
|
| Other Expenses |
-$105.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$42.87 M
|
$27.55 M
|
$23.41 M
|
$32.57 M
|
$38.63 M
|
$43.76 M
|
$48.85 M
|
$49.22 M
|
$56.52 M
|
$36.98 M
|
| Cost And Expenses |
$42.97 M
|
$27.55 M
|
$23.41 M
|
$32.57 M
|
$38.63 M
|
$43.76 M
|
$48.85 M
|
$49.22 M
|
$56.52 M
|
$36.98 M
|
| Interest Income |
$2.51 M
|
$1.82 M
|
$1.58 M
|
$654.00 K
|
$0.00
|
$540.00 K
|
$2.18 M
|
$2.28 M
|
$861.00 K
|
$601.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$15.00 K
|
$540.00 K
|
$2.18 M
|
$2.28 M
|
$0.00
|
$601.00 K
|
| Depreciation & Amortization |
$105.00 K
|
$85.00 K
|
$151.00 K
|
$367.00 K
|
$460.00 K
|
$632.00 K
|
$743.00 K
|
$847.00 K
|
$842.00 K
|
$594.00 K
|
| EBITDA |
-$42.97 M |
-$27.46 M |
-$23.26 M |
-$32.20 M |
-$38.17 M |
-$5.36 M |
-$48.11 M |
-$46.09 M |
-$54.82 M |
-$35.78 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$27.69 M
|
-$34.75 M
|
-$3.62 M
|
-$8.74 M
|
-$4.61 M
|
$37.77 M
|
$2.18 M
|
$2.28 M
|
$861.00 K
|
$601.00 K
|
| Income Before Tax |
-$15.28 M
|
-$62.29 M
|
-$27.03 M
|
-$41.31 M
|
-$43.24 M
|
-$6.00 M
|
-$46.67 M
|
-$46.94 M
|
-$55.66 M
|
-$36.38 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$15.28 M
|
-$62.29 M
|
-$27.03 M
|
-$41.31 M
|
-$43.24 M
|
-$6.00 M
|
-$46.67 M
|
-$46.94 M
|
-$55.66 M
|
-$36.38 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.19 |
-1.02 |
-0.5628 |
-0.89 |
-1.03 |
-0.2 |
-1.49 |
-1.71 |
-2.72 |
-2.36 |
| EPS Diluted |
-0.53 |
-1.02 |
-0.5628 |
-0.89 |
-1.03 |
-0.2 |
-1.49 |
-1.71 |
-2.72 |
-2.36 |
| Weighted Average Shares Out |
$78.96 M
|
$60.99 M
|
$48.03 M
|
$46.55 M
|
$41.85 M
|
$29.48 M
|
$29.35 M
|
$27.51 M
|
$20.49 M
|
$15.42 M
|
| Weighted Average Shares Out Diluted |
$79.74 M
|
$60.99 M
|
$48.03 M
|
$46.55 M
|
$41.85 M
|
$29.48 M
|
$29.35 M
|
$27.51 M
|
$20.49 M
|
$15.42 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
